ITEMS IN AFP WITH KEYWORD:
Mar 15, 2015 Issue
Screening for Oral Cancer: Recommendation Statement [U.S. Preventive Services Task Force]
The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for oral cancer in asymptomatic adults.
The U.S. Preventive Services Task Force (USPSTF) gave lung cancer screening a B recommendation on the basis of the reductions in disease-specific mortality and all-cause mortality seen in the National Lung Screening Trial (NLST). The NLST does not consider cost or cost-effectiveness in its recommend...
Jan 15, 2015 Issue
Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women [Putting Prevention into Practice]
L.M. is a 37-year-old nonsmoking woman who is not taking any medications and has no significant past medical problems. Three of her female relatives have a history of breast cancer: her mother (diagnosed at 49 years of age, before menopause), her paternal grandmother (diagnosed at 72 years of age), ...
Family physicians play a key role in identifying patients in need of increased cancer surveillance because of a personal or family history of cancer. How does one know if a patient warrants genetic testing for hereditary cancer predisposition?
Jan 15, 2015 Issue
Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Recommendation Statement [U.S. Preventive Services Task Force]
The U.S. Preventive Services Task Force (USPSTF) recommends that primary care clinicians screen women who have family members with breast, ovarian, tubal, or peritoneal cancer with one of several screening tools designed to identify a family history that may be associated with an increased risk of p...
Cancer screening is an essential part of family medicine, although changing recommendations have led to confusion among physicians and patients. Learn about the controversies and current recommendations.
Fecal DNA testing is more sensitive but less specific than fecal immunochemical testing (FIT), and as a result, has a higher false-positive rate. It is also more expensive than other noninvasive alternatives such as FIT. We do not know which test will be better at reducing mortality.
Immunochemical FOBTs, such as OC-Micro, OC-Sensor, or OC-Light, are moderately sensitive (73% to 89%) and highly specific (92% to 95%) for identifying colorectal cancer. In comparison, Hemoccult Sensa has a lower sensitivity (64% to 80%) and specificity (87% to 90%). Immunochemical FOBTs also have the advantage of requiring only one sample.
In patients screened for lung cancer using low-dose computed tomography (LDCT), more than 18% of all lung cancers found are slow-growing and will not cause symptoms or harm during an average 6.4 years of follow-up. This risk of overdiagnosis should be part of the discussion regarding whether to screen.
M.B., a woman with diabetes mellitus, presents to your office for an annual well visit. M.B. reports having smoked one and a half packs of cigarettes daily for 20 years. Her neighbor was recently diagnosed with lung cancer, and M.B. requests to be tested for lung cancer, too.